Bevacizumab for Neovascular Age-related Macular Degeneration

Peking University

Status: Completed

Conditions: Exudative Age-related Macular Degeneration

Treatments: Drug: Bevacizumab; Drug: Bevacizumab 1

Study type: Interventional

Funder types: Other

Identifiers

NCT01306591

Bevacizumab for nAMD

Details and patient eligibility

About

Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.

Enrollment: 210 patients

Sex: All

Ages: 50 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of neovascular Age-related macular degeneration
• Signed informed consent

Exclusion criteria

• No other ocular fundus diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

210 participants in 2 patient groups

Bevacizumab 1

Active Comparator group

Treatment:

Drug: Bevacizumab 1

Bevacizumab 2

Active Comparator group

Treatment:

Drug: Bevacizumab